Pharmaceutical manufacturers are rapidly shifting their obesity drug pipelines toward oral medications and infrequent dosing schedules to capture a larger share of the global weight-loss market. While Eli Lilly and Novo Nordisk currently maintain a market duopoly with injectable GLP-1 treatments, competitors like Pfizer, Amgen, and Zealand Pharma are advancing mid-stage clinical trials for pills and long-acting injections that aim to reduce patient treatment burdens.
The Shift Toward Oral Obesity Medications
Major drugmakers are prioritizing the development of oral weight-loss pills to increase accessibility and patient compliance. Eli Lilly currently markets its small-molecule pill, orforglipron, while Novo Nordisk continues to expand the reach of its oral GLP-1 options. According to data from Novo Nordisk, prescriptions for its oral semaglutide formulations have seen significant uptake, reaching millions of patients within months of market entry.
Other firms are attempting to close this gap. Both Structure Therapeutics and AstraZeneca have reported positive mid-stage data for their respective oral GLP-1 candidates. If these companies successfully navigate Phase 3 clinical trials, market analysts expect these products to reach commercial availability by approximately 2029. Structure Therapeutics CEO Ray Stevens recently stated that the market remains large enough to accommodate multiple small-molecule competitors, emphasizing that increased competition typically benefits patients through expanded access.
Innovations in Dosing Frequency
Beyond oral delivery, manufacturers are testing long-acting injectable treatments to improve the patient experience. Pfizer is currently evaluating a monthly injectable candidate, a shift from the weekly administration required by current market leaders. Amgen is pursuing an even less frequent schedule, with development programs investigating drugs that could be administered as infrequently as four times per year.
Susan Sweeney, Amgen’s executive vice president of obesity and related conditions, noted that reducing injection frequency allows patients to manage their health without the daily or weekly reminder of their chronic condition. This strategy aims to differentiate new entrants from the current standard of weekly GLP-1 injections like Wegovy and Zepbound.
Emerging Targets Beyond GLP-1
While GLP-1 and GIP receptor agonists currently dominate the sector, companies are exploring alternative hormonal pathways to manage obesity. Zealand Pharma, in partnership with Roche, is testing petrelintide, an amylin analog that regulates satiety. Clinical trial data presented at the American Diabetes Association’s Scientific Sessions indicated that while weight loss percentages for petrelintide were lower than those observed with current GLP-1 drugs, the treatment showed a favorable profile regarding gastrointestinal side effects.
Eli Lilly is simultaneously advancing its own amylin analog, eloralintide, which is already in Phase 3 trials. Additionally, Lilly’s triple-agonist drug, retatrutide, has demonstrated significant efficacy in clinical settings. According to trial results presented by Lilly, participants at the highest dose achieved an average weight loss of 28%, with nearly half of the cohort losing more than 30% of their body weight.
Market Outlook and Pricing Pressures
The long-term economic viability of the obesity drug market remains tied to pricing and insurance coverage. Goldman Sachs analyst Asad Haider notes that the primary uncertainty facing the industry is not market volume, but the eventual price ceiling for these therapies.
The competitive landscape is influenced by:
- Pricing Competition: Both Novo Nordisk and Eli Lilly have faced pressure to lower prices due to competition from compounding pharmacies.
- Insurance Access: Expanded coverage for Medicare beneficiaries is expected to lower out-of-pocket costs to approximately $50 per month for millions of seniors.
- Market Segmentation: Novo Nordisk CEO Mike Doustdar has suggested that the future of obesity treatment may mirror the mental health sector, where various conditions are treated with specific, targeted medications rather than a one-size-fits-all approach.
As of 2024, the World Health Organization estimates that 890 million people worldwide are considered obese, providing a substantial target demographic for the current wave of pharmaceutical innovation.
Related reading